Lilly sues Indianapolis clinic for selling split doses of popular weight-loss drugs
The drugmaker accuses Premier Weight Loss of risking patients’ health by selling altered, unsterile versions of its blockbuster drugs Mounjaro and Zepbound.
The drugmaker accuses Premier Weight Loss of risking patients’ health by selling altered, unsterile versions of its blockbuster drugs Mounjaro and Zepbound.
At least 14 states already cover the cost of GLP-1 medications for obesity treatment for patients on Medicaid. Indiana is not one of them.
Syra Health Corp. plans to offer stock on the over-the-counter market after the company failed to meet Nasdaq Stock Market’s price requirements for its shares.
The company said its goal is to reduce wait times for patients seeking access to specialists, creating more opportunities for early diagnosis and intervention.
Aside from building four new plants, Johnson & Johnson said that it will expand several existing sites.
“People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of management.”
Indianapolis has been awash in Big Ten logos amid the conference’s basketball tournaments. But Indy is home to another sort of Big Ten gathering—one focused on improving cancer research.
Speaking at IBJ’s Technology Power Breakfast on Monday, U.S. Sen. Todd Young of Indiana also discussed the challenge of striking a balance between encouraging innovation in artificial intelligence and developing necessary guardrails.
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.
The pre-clinical West Lafayette-based medical device startup is working to develop a new “microstructred” catheter to remove blood clots that cause strokes.
For Elevance Health and other big insurers, 2024 devolved into something of an annus horribilis over the year’s final weeks. And 2025 holds more challenges but also an opportunity for a rebound.
The foundry will give the pharmaceutical maker the ability to research new ways of producing medicines.
President Donald Trump has instructed his administration to scrutinize the “threat” to children posed by antidepressants, stimulants and other common psychiatric drugs.
Hoosier farmers are on edge as the bird flu—officially the highly pathogenic avian influenza, or HPAI—continues to menace big and small flocks alike three years into this outbreak.
The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.’s Omvoh, a new therapy to treat Chron’s disease and ulcerative colitis, is the company’s latest step into the treatment of gastrointestinal diseases.
Pete Yonkman, president of Cook Group and Cook Medical, was among the speakers Monday at the official launch of the new Indiana University IU Launch Accelerator for Biosciences, or IU LAB.
Syra Health is looking to its new AI-powered app, Syrenity, to help it reach profitability and establish itself as a provider of high-tech mental health services.
The health care company has expanded its reach over the past seven years to become a master developer for a sprawling project on the south side of Interstate 70 in western Hancock County.
AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially helping Eli Lilly and Co. and other companies develop new medicines more quickly.
Kristin Sherman leads startup Kovina Therapeutics, which is still in the early stages of developing ways to stop human papillomavirus infections before cancer develops and to treat HPV cancers after detection.